Stay updated on PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial
Sign up to get notified when there's something new on the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page.

Latest updates to the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no study data or page content were modified. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedThe page footer shows a revision update from v3.4.0 to v3.4.1, indicating a minor software update. No user-facing content or study details were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedShow glossary was added to the page. The page metadata now includes 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' with a new revision tag v3.4.0 (replacing v3.3.4).SummaryDifference0.2%

- Check42 days agoChange DetectedSite revision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a dedicated Locations section showing Durham, North Carolina (Duke Cancer Center) and updated the page's revision to v3.3.3. Removed the HHS Vulnerability Disclosure link.SummaryDifference0.2%

- Check92 days agoChange DetectedThe page revision label was updated from v3.2.0 to v3.3.2 in the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page.